Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
Origin | Publication funded by an institution |
---|
Origin | Publication funded by an institution |
---|
Claudia Tapia : Connect in order to contact the contributor
https://hal.u-pec.fr/hal-04145712
Submitted on : Thursday, June 29, 2023-1:32:19 PM
Last modification on : Thursday, November 23, 2023-2:18:03 PM
Long-term archiving on : Saturday, September 30, 2023-6:56:25 PM